Yi Lu1, Jenny Huang1,2, Natalia V Neverova1, Kim-Lien Nguyen1,3,2. 1. Division of Cardiology, David Geffen School of Medicine at UCLA and VA Greater Los Angeles Healthcare System. 2. Diagnostic Cardiovascular Imaging Research Laboratory, Department of Radiology, David Geffen School of Medicine at UCLA. 3. Physics and Biology in Medicine Graduate Program, University of California, Los Angeles.
Abstract
PURPOSE OF REVIEW: We aim to discuss the diagnostic use of ultra-small superparamagnetic iron oxide (USPIOs) including ferumoxytol in targeted cardiovascular magnetic resonance imaging (MRI). RECENT FINDINGS: Ferumoxytol is the only USPIO clinically available in the U.S. and is a negatively charged USPIO that has potential use for tracking and characterization of macrophage-infiltrated cardiovascular structures. As an iron supplement that is approved for treatment of iron deficiency anemia, the iron core of ferumoxytol is incorporated into the body once it is phagocytosed by macrophages. In organs or tissues with high inflammatory cellular infiltration, such as atherosclerotic plaques and myocardial infarction, localization of iron-laden macrophages can be visualized on delayed MRI. The iron core of ferumoxytol alters the magnetic susceptibility and results in shortening of T2* and T2 relaxation rates. Areas with high concentration appear hypointense (negative contrast) on T2 and T2* MRI. Recently, in vitro findings support the potential specificity of ferumoxytol interactions with macrophage subtypes, which has implications for therapeutic interventions. With increasing concerns about gadolinium retention in the brain and other tissues, the value of ferumoxytol-enhanced MR for targeted clinical imaging is aided by its positive safety profile in patients with impaired renal function. SUMMARY: This paper discusses pharmacokinetic properties of USPIOs with a focus on ferumoxytol, and summarizes relevant in vitro, animal, and human studies investigating the diagnostic use of USPIOs in targeted contrast-enhanced imaging. We also discuss future directions for USPIOs as targeted imaging agents and associated challenges.
PURPOSE OF REVIEW: We aim to discuss the diagnostic use of ultra-small superparamagnetic iron oxide (USPIOs) including ferumoxytol in targeted cardiovascular magnetic resonance imaging (MRI). RECENT FINDINGS: Ferumoxytol is the only USPIO clinically available in the U.S. and is a negatively charged USPIO that has potential use for tracking and characterization of macrophage-infiltrated cardiovascular structures. As an iron supplement that is approved for treatment of iron deficiency anemia, the iron core of ferumoxytol is incorporated into the body once it is phagocytosed by macrophages. In organs or tissues with high inflammatory cellular infiltration, such as atherosclerotic plaques and myocardial infarction, localization of iron-laden macrophages can be visualized on delayed MRI. The iron core of ferumoxytol alters the magnetic susceptibility and results in shortening of T2* and T2 relaxation rates. Areas with high concentration appear hypointense (negative contrast) on T2 and T2* MRI. Recently, in vitro findings support the potential specificity of ferumoxytol interactions with macrophage subtypes, which has implications for therapeutic interventions. With increasing concerns about gadolinium retention in the brain and other tissues, the value of ferumoxytol-enhanced MR for targeted clinical imaging is aided by its positive safety profile in patients with impaired renal function. SUMMARY: This paper discusses pharmacokinetic properties of USPIOs with a focus on ferumoxytol, and summarizes relevant in vitro, animal, and human studies investigating the diagnostic use of USPIOs in targeted contrast-enhanced imaging. We also discuss future directions for USPIOs as targeted imaging agents and associated challenges.
Authors: M E Kooi; V C Cappendijk; K B J M Cleutjens; A G H Kessels; P J E H M Kitslaar; M Borgers; P M Frederik; M J A P Daemen; J M A van Engelshoven Journal: Circulation Date: 2003-04-28 Impact factor: 29.690
Authors: Gerda B Toth; Csanad G Varallyay; Andrea Horvath; Mustafa R Bashir; Peter L Choyke; Heike E Daldrup-Link; Edit Dosa; John Paul Finn; Seymur Gahramanov; Mukesh Harisinghani; Iain Macdougall; Alexander Neuwelt; Shreyas S Vasanawala; Prakash Ambady; Ramon Barajas; Justin S Cetas; Jeremy Ciporen; Thomas J DeLoughery; Nancy D Doolittle; Rongwei Fu; John Grinstead; Alexander R Guimaraes; Bronwyn E Hamilton; Xin Li; Heather L McConnell; Leslie L Muldoon; Gary Nesbit; Joao P Netto; David Petterson; William D Rooney; Daniel Schwartz; Laszlo Szidonya; Edward A Neuwelt Journal: Kidney Int Date: 2017-04-20 Impact factor: 10.612
Authors: Ali Yilmaz; Michael A Dengler; Heiko van der Kuip; Handan Yildiz; Sabine Rösch; Siegfried Klumpp; Karin Klingel; Reinhard Kandolf; Xavier Helluy; Karl-Heinz Hiller; Peter M Jakob; Udo Sechtem Journal: Eur Heart J Date: 2012-10-26 Impact factor: 29.983
Authors: Kim-Lien Nguyen; Takegawa Yoshida; Fei Han; Ihab Ayad; Brian L Reemtsen; Isidro B Salusky; Gary M Satou; Peng Hu; J Paul Finn Journal: J Magn Reson Imaging Date: 2016-08-02 Impact factor: 5.119
Authors: Colin G Stirrat; Shirjel R Alam; Thomas J MacGillivray; Calum D Gray; Marc R Dweck; Kevin Dibb; Nick Spath; John R Payne; Sanjay K Prasad; Roy S Gardner; Saeed Mirsadraee; Peter A Henriksen; Scott Ik Semple; David E Newby Journal: Heart Date: 2017-10-06 Impact factor: 7.365